Free Trial
Portfolio Monitoring Tools for the A.I. EraStart My Trial

GSK (GSK) Stock Forecast & Price Target

GSK logo
GBX 1,640.25 +0.25 (+0.02%)
As of 05:27 AM Eastern
Compare

GSK - Analysts' Recommendations and Stock Price Forecast (2025)

Consensus Rating

Hold
Based on 3 Analyst Ratings
Sell
0
Hold
2
Buy
1

Based on 3 Wall Street analysts who have issued ratings for GSK in the last 12 months, the stock has a consensus rating of "Hold." Out of the 3 analysts, 2 have given a hold rating, and 1 has given a buy rating for GSK.

Consensus Price Target

GBX 1,637.50
According to the 3 analysts' twelve-month price targets for GSK, the average price target is GBX 1,637.50. The highest price target for GSK is GBX 2,100, while the lowest price target for GSK is GBX 1,400. The average price target represents a forecasted downside of -0.17% from the current price of GBX 1,640.25.
MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
Get the Latest News and Ratings for GSK and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for GSK and its competitors.

Sign Up
By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

GSK Analyst Ratings Over Time

TypeCurrent Forecast
10/10/24 to 10/10/25		1 Month Ago
9/10/24 to 9/10/25		3 Months Ago
7/12/24 to 7/12/25		1 Year Ago
10/11/23 to 10/10/24
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
1 Buy rating(s)
1 Buy rating(s)
2 Buy rating(s)
5 Buy rating(s)
Hold
2 Hold rating(s)
2 Hold rating(s)
1 Hold rating(s)
1 Hold rating(s)
Sell
0 Sell rating(s)
1 Sell rating(s)
1 Sell rating(s)
1 Sell rating(s)
Consensus Price TargetGBX 1,637.50GBX 1,637.50GBX 1,525GBX 1,842.50
Consensus RatingHoldHoldHoldModerate Buy

GSK Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

GSK Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

GSK Stock vs. The Competition

TypeGSKMedical Companies
Consensus Rating Score
2.33
2.33
Consensus RatingHoldHold
News Sentiment Rating
Neutral News

See Recent GSK News
Positive News
Export to Excel
DateBrokerageAnalystActionRatingPrice TargetReport Date
Upside/Downside		Details
10/3/2025JPMorgan Chase & Co.
2 of 5 stars		 Reiterated RatingUnder review
8/27/2025Shore Capital
1 of 5 stars		 Reiterated RatingBuyGBX 2,100+41.89%
7/31/2025Deutsche Bank Aktiengesellschaft
3 of 5 stars		 Reiterated RatingHoldGBX 1,450+1.29%
7/18/2025Berenberg Bank
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		 Reiterated RatingHoldGBX 1,600+17.69%
7/5/2024Citigroup
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		 Lower TargetBuyGBX 2,120 ➝ GBX 1,900+24.79%
6/27/2024Jefferies Financial Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		 Reiterated RatingBuyGBX 2,100+38.25%
5/7/2024Barclays
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		 Reiterated RatingEqual WeightGBX 1,725-1.96%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Friday at 05:51 AM ET.


Should I Buy GSK Stock? GSK Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Thursday, October 9, 2025. Please send any questions or comments about these GSK pros and cons to contact@marketbeat.com.

GSK
Bull Case

green Wall Street bull icon

Here are some ways that investors could benefit from investing in GSK plc:

  • The current stock price is around $21.76, which has recently crossed above its 200-day moving average, indicating potential upward momentum.
  • GSK plc has reached a new 52-week high, reflecting strong market performance and investor confidence.
  • Analysts have given GSK plc a consensus target price of approximately GBX 1,637.50, suggesting potential for price appreciation.
  • The company reported a solid earnings per share of GBX 75.30 for the last quarter, indicating profitability and operational efficiency.
  • GSK plc has a relatively low beta of 0.31, suggesting that it is less volatile compared to the overall market, which may appeal to risk-averse investors.

GSK
Bear Case

red Wall Street bear icon

Investors should be bearish about investing in GSK plc for these reasons:

  • Despite recent highs, the stock has been rated with a mix of "Hold" and "Underweight" by analysts, indicating uncertainty about future performance.
  • The company has a high price-to-earnings (P/E) ratio, which may suggest that the stock is overvalued compared to its earnings.
  • GSK plc has a significant debt-to-equity ratio of 114.64, indicating a reliance on debt financing that could pose risks in a rising interest rate environment.
  • Recent analyst reports have shown some price target reductions, which may signal caution among investors regarding GSK's growth prospects.
  • The company's net margin of 8.02% may be considered low in comparison to industry standards, potentially limiting profitability growth.

GSK Forecast - Frequently Asked Questions

According to the research reports of 3 Wall Street equities research analysts, the average twelve-month stock price forecast for GSK is GBX 1,637.50, with a high forecast of GBX 2,100 and a low forecast of GBX 1,400.

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for GSK in the last year. There are currently 2 hold ratings and 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "hold" GSK shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in GSK, but not buy additional shares or sell existing shares.

According to analysts, GSK's stock has a predicted downside of -0.17% based on their 12-month stock forecasts.

GSK has been rated by research analysts at Berenberg Bank, Deutsche Bank Aktiengesellschaft, JPMorgan Chase & Co., and Shore Capital in the past 90 days.

Analysts like GSK more than other "medical" companies. The consensus rating score for GSK is 2.33 while the average consensus rating score for "medical" companies is 2.33. Learn more on how GSK compares to other companies.

Related Companies
Today's Ratings
Top-Rated Stocks
More Ratings Tools

This page (LON:GSK) was last updated on 10/10/2025 by MarketBeat.com Staff
From Our Partners
"I'm risking my reputation on this"
The Fed rate cut truth they don't want you to know The Fed's 25 basis point cut isn't just monetary policy…...
Crypto 101 Media | Sponsoredtc pixel
REVEALED: Something Big Happening Behind White House Doors
What I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...
Paradigm Press | Sponsoredtc pixel
Robinhood warning
A strange chasm is coming to Wall Street... It's already creating millionaires and billionaires at the fast...
Stansberry Research | Sponsoredtc pixel
1 Hour Once A Day
My top income trading expert, Dave Aquino, just released a 1-hour trading strategy designed specifically to he...
Base Camp Trading | Sponsoredtc pixel
Buy UBER immediately
BULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...
Chaikin Analytics | Sponsoredtc pixel
URGENT: The Market's 3 Red Flags Are Flashing
Here’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...
StockEarnings | Sponsoredtc pixel
Claim Your Share of $5.39 BILLION in AI Equity Checks
The U.S. government just took advantage of Public Law 81-774 to crack down on AI companies... In turn, enfo...
Angel Publishing | Sponsoredtc pixel
INVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting Off
Right now, we’re witnessing a monumental shift in the world.
Traders Agency | Sponsoredtc pixel